BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/29/2014 7:34:00 PM | Browse: 959 | Download: 944
|
Received |
|
2014-02-16 20:37 |
|
Peer-Review Started |
|
2014-02-16 21:20 |
|
To Make the First Decision |
|
2014-04-15 19:31 |
|
Return for Revision |
|
2014-04-21 19:47 |
|
Revised |
|
2014-05-01 20:57 |
|
Second Decision |
|
2014-06-13 11:53 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2014-06-13 12:38 |
|
Articles in Press |
|
2014-06-13 13:04 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2014-08-07 17:17 |
|
Typeset the Manuscript |
|
2014-10-20 16:41 |
|
Publish the Manuscript Online |
|
2014-10-29 19:34 |
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Review |
Article Title |
Halofuginone for fibrosis, regeneration and cancer in the gastrointestinal tract
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Mark Pines |
Funding Agency and Grant Number |
|
Corresponding Author |
Mark Pines, PhD, Institute of Animal Sciences, the Volcani Center, PO Box 6, Bet Dagan 50250, Israel. mark.pines@mail.huji.ac.il |
Key Words |
Stellate cell; Myofibroblast; Transforming growth factor a; Extracellular matrix; Cancer |
Core Tip |
Fibrosis is a pathological process associated with excessive deposition of extracellular matrix that leads to destruction of organ architecture and function. Fibrosis contributes enormously to deaths worldwide, thus therapies are of a great need. The concept of common fibrosis pathways that could be therapeutic targets in all organs is an attractive one. Halofuginone is a novel anti-fibrotic therapy that inhibits tissue fibrosis, regeneration, and development of tumors in tissues along the gastrointestinal tract. At present halofuginone is being evaluated in a clinical trial for another fibrotic indication, and any clinical success there would allow its use for all other fibrotic indications. |
Publish Date |
2014-10-29 19:34 |
Citation |
Pines M. Halofuginone for fibrosis, regeneration and cancer in the gastrointestinal tract. World J Gastroenterol 2014; 20(40): 14778-14786 |
URL |
http://www.wjgnet.com/1007-9327/full/v20/i40/14778.htm |
DOI |
http://dx.doi.org/10.3748/wjg.v20.i40.14778 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345